Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02904226 · ClinicalTrials.gov registry record · Phase 1
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
A Phase 1 study, sponsored by Jounce Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 242
- Enrollment target
NCT02904226: Completed Phase 1 study, sponsored by Jounce Therapeutics.
NCT02904226 is a Phase 1 study that has completed, run by Jounce Therapeutics. The registered enrollment target is 242 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (303% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02904226, a Phase 1 study, has completed, sponsored by Jounce Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 242 participants
- Enrollment target
Study Summary
JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of JTX-2011 alone and in combination with nivolumab, ipilimumab, or pembrolizumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Primary Outcome
Number of participants with an adverse event occurring from the time of informed consent until resolution or new therapy initiated or for 28 days post final dose if no new therapy is initiated
Interventions
- DRUG Pembrolizumab
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG JTX-2011
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2016-08 |
| Est. Completion | 2020-07-01 |
| Phase | Phase 1 |
What the finished NCT02904226 record still lists
NCT02904226 is an interventional study that assigns participants to a tested intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (303% higher).
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT02904226 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02904226 about?
NCT02904226 is a clinical study titled "JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors". JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of JTX-2011 alone and in combination with nivolumab, ipilimumab, or pembrolizumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase ...
What is the current status of trial NCT02904226?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 242 participants. The study started on 2016-08. Estimated completion is 2020-07-01.
What interventions are being tested in trial NCT02904226?
The interventions under investigation include: Pembrolizumab (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG), JTX-2011 (DRUG).
Who is sponsoring clinical trial NCT02904226?
This trial is sponsored by Jounce Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02904226's enrollment target sits among peer trials
242 194th of 2000 higher than 1,805 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia